Many posters will already have read the old CCZ report, however worth a look if you haven't, as it discusses the issue of ageing trials (I assume in the report referred to as "product registration"). The report is from December 2009 so they obviously knew about this process back then. Page 3 of the report states:
"...SA (Sanofi Aventis)needs to secure product registrations using the RTF (ready to fills). This is an expensive process that needs to be taken out in all jurisdictions in which the drug and RTF is to be sold and takes 12 to 18 months... cannot commence until UNI's 60M pa automated prioduction line is in operation. Once they have product, SA and any other pharma company... will build inventory ahead of the post registraion product launch. The actual registration is a formality and hence the willingness of SA and other pharma companies to buy for inventory.".
Also interesting to note the projected Unifill sales used by the analyst (in units, not dollars): 30M for 12mths to Jun-2011, 140M to Jun-2012, 290M to Jun-2013, 440M to Jun-2014, and 590M to Jun-2015.
